Can obesity cause cancer?

Share This Post

Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system), but there is no unified conclusion on the relationship with cancer in other parts. An umbrella review published in Annals of Oncology at the end of 2017, comprehensively analyzing the relationship between 26 BMI and cancer riskta analysis, and strive to bring the most authoritative conclusions to readers.

The study only included evaluation of the quantitative response between BMI and the risk of cancer analysis, a total of 26 articles. Use umbrella review (ie multiple meta analysis to review), re-analyzed the relationship between BMI and 20 types of cancer.

The results of the study showed that five types of cancer (leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer, and renal cell carcinoma) had the highest correlation strength with BMI; three types of cancer (malignant melanoma, non-Hodgkin) Lymphoma and esophageal adenocarcinoma) and BMI reach a moderate level of strength; for brain and central nervous system tumors, breast cancer, colon cancer, gallbladder cancer, lung cancer, liver cancer, ovarian cancer and thyroid cancer, there is a low-grade BMI Degree of association; there is no association between the occurrence of bladder cancer, gastric cancer and prostate cancer and BMI.

The relationship between increased BMI and the occurrence of cancer varies greatly between different cancers. According to analysis, the occurrence of leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer and renal cell carcinoma is strongly associated with the increase in BMI.

Body mass index and 20-specific cancers: re-analyses of dose-response meta-analyses of observational studies. Ann Oncol. 2017 Dec 28. doi: 10.1093 / annonc / mdx819. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy